Carla This will saves a ton of patients, and $$$$

This Times Square message wasn’t funded by a marketing budget. It was donated by the father of a cancer patient whose life was impacted by our work. We’re trying to preserve a technology that tests drugs directly on live tumor cells — so patients aren’t treated by trial and

First principles lead to tools. The PARIS test was built on a simple idea: test dozens of FDA-approved drugs directly on a patient’s own cancer cells — before treating the patient. This approach has helped patients with few or no remaining options. For example an ovarian cancer

We’ve seen this repeatedly in rare and refractory cancers. Genomics tells us what might be wrong. Functional testing shows what actually works. Patients need both. Here results from the PARIS test presented AACR annual meeting 2025 aacrjournals.org/cancerres/arti…

ASCO daily news: on the importance of recognizing rare cancers, listening to patients, and performing NGS to optimize therapy dailynews.ascopubs.org/do/strategic-a…

A few years ago, just after Christmas, I received a call from the husband of a patient. He said: “I wanted to thank you. My wife is doing well. Because of the testing, she was able to spend and really enjoy Christmas with our kids, for the first time in years.” I still think

Most cancer treatment is still based on educated trial and error. We sequence tumors. We follow evidence-based guidelines. And despite everyone doing their best, we often don’t know which drug will work for this patient. That uncertainty has real consequences

I am sharing a quick update for those who may not have seen this yet. As of 9/29/25, I have had the honor of serving as Director of the National Cancer Institute. I will be sharing updates on cancer research progress from Dr. Anthony Letai. Feel free to follow me there.

Good timing with #GI26. 🗞️ Published today📝 Nature Communications Tucatinib➕Trastuzumab Mountaineer 🏔️ regimen HER2 ➕/RAS➖Metastatic colorectal cancer #CRCSM 🔗 nature.com/articles/s4146… 🔑 findings are that responses seen regardless of the method of testing 🔬🆚🧬🆚🩸 OncoAlert

What if clinical trial responses could be turned into 100%? Only 10 of 25 patients benefited in this study, ascopost.com/news/january-2… that is already strong relative to most clinical trials, yet the majority of patients is left behind. I am not surprised, clear cells is not a

Happy to report that the PARIS test laboratory will re-open on February 2nd. Thank you to Philanthropic donations to Cure First. Cancer patients and oncologists can reach us to order the test via email: [email protected] or calling: 1 (425) 366-7614.

The first week report since the PARIS test has reopened: day 2, a leyomyosarcoma surgical resection, day 3 received requests for 6 additional samples, including a brain metastasis. Our whole team is back on board with Cure First (cure-first.org). Miracles do happen.

Finally, the title of Nature briefing today is"The age of animal models in waning". It has been long known that oncology drugs validated in rodents using long established cancer cell lines, don't ensure success. Having worked to perfect human 3D cancer models and developed one

If you or someone you love is facing cancer, please see this GoFundMe campaign: gofundme.com/f/how-do-you-k…. Every cancer is different. Today we can grow a patient’s tumor cells in the lab and test dozens of cancer drugs before treatment begins, helping identify the treatments most